Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,620,000
$81.62 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 03
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,440
-5.65%
|
$364,080
$82.44 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,850
-3.19%
|
$157,250
$85.01 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,850
+3.09%
|
$116,550
$63.1 P/Share
|
|
May 02
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.97%
|
$410,000
$82.91 P/Share
|
|
Apr 30
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.15%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.41%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245
+0.31%
|
$16,660
$68.65 P/Share
|
|
Apr 30
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
301
+0.53%
|
$20,468
$68.65 P/Share
|
|
Apr 30
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.42%
|
$20,400
$68.65 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,820,000
$91.26 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,800,000
$90.99 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 10
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,286
-12.4%
|
$205,740
$90.0 P/Share
|
|
Mar 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
24,602
-30.58%
|
$2,164,976
$88.34 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,510
-23.3%
|
$789,330
$83.81 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.68%
|
$790,000
$79.7 P/Share
|
|
Mar 18
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-1.98%
|
$30,876
$83.87 P/Share
|
|
Mar 15
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+20.06%
|
-
|
|
Mar 15
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,424
-20.68%
|
$1,695,192
$83.87 P/Share
|
|
Mar 15
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,550
+9.65%
|
-
|
|
Mar 15
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,699
-21.24%
|
$1,801,017
$83.87 P/Share
|
|
Mar 15
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,260
+9.13%
|
-
|
|
Mar 15
2024
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
33,485
-14.54%
|
$2,779,255
$83.87 P/Share
|
|
Mar 15
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
18,240
+7.34%
|
-
|
|
Mar 15
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,789
-22.44%
|
$1,725,487
$83.87 P/Share
|
|
Mar 15
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,400
+10.96%
|
-
|
|
Mar 15
2024
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
85,209
-15.21%
|
$7,072,347
$83.87 P/Share
|
|
Mar 15
2024
|
Alexander Hardy Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,780
+18.12%
|
-
|
|
Mar 15
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,580
-24.01%
|
$1,874,140
$83.87 P/Share
|
|
Mar 06
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$86,000
$86.71 P/Share
|
|
Mar 05
2024
|
Henry J Fuchs President, Worldwide R&D |
SELL
Open market or private sale
|
Direct |
35,341
-14.28%
|
$3,003,985
$85.18 P/Share
|
|
Mar 05
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$85,000
$85.51 P/Share
|
|
Mar 05
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,000
-4.08%
|
$348,000
$87.07 P/Share
|
|
Feb 27
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,125
+13.61%
|
-
|
|
Feb 27
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,187
+12.95%
|
-
|
|
Feb 27
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,187
+12.46%
|
-
|
|
Feb 27
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
53,204
+6.96%
|
-
|
|
Feb 27
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,243
+12.04%
|
-
|
|
Feb 27
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$90,000
$90.35 P/Share
|
|
Feb 27
2024
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,601
+8.21%
|
-
|
|
Feb 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-3.45%
|
$1,320,000
$88.28 P/Share
|
|
Feb 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.34%
|
$945,000
$63.1 P/Share
|
|
Feb 08
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-3.45%
|
$1,335,000
$89.77 P/Share
|
|
Feb 08
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.34%
|
$945,000
$63.1 P/Share
|
|
Jan 18
2024
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
40
+0.01%
|
$3,680
$92.6 P/Share
|
|
Jan 10
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$960,000
$96.38 P/Share
|